See every side of every news story
Get Started
SubscribeLogin
Pope Francis
Vatican
Volodymyr Zelenskyy
Ukraine War
Olaf Scholz
Donald Trump
Elon Musk
Israel-Hamas Conflict
Basketball
Vladimir Putin
Manchester City
Hamas
Published • loading... • Updated

Orlabrutininb is backACTRIMS 2025

Summary by Multiple Sclerosis Research Blog
Tweet Biogen bought the rights to orlabrutinib and mysteriously sent it back to China to develop their own Brutons trysosine kinase inhibitor. All have so far been successful in phase II against placebo and this is also true for orlabrutinib seen at ACTRIMS. This is a covalent binder meaning it is irreversible when it binds and means you have to wait for the BTK to regenerate for activity to return. This occurs pretty quickly. Biogen went off to…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Multiple Sclerosis Research BlogMultiple Sclerosis Research Blog

Orlabrutininb is backACTRIMS 2025

Tweet Biogen bought the rights to orlabrutinib and mysteriously sent it back to China to develop their own Brutons trysosine kinase inhibitor. All have so far been successful in phase II against placebo and this is also true for orlabrutinib seen at ACTRIMS. This is a covalent binder meaning it is irreversible when it binds and means you have to wait for the BTK to regenerate for activity to return. This occurs pretty quickly. Biogen went off to…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Multiple Sclerosis Research Blog broke the news in on Saturday, February 22, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

China

China

News
For You
Search
BlindspotLocal